Antimicrobial resistance, a global threat
B·Debate and ISGlobal bring together experts from around the world in Barcelona to debate how to improve resistance to drugs and the lack of new drugs to treat infections caused by resistant bacteria.
By Biocat
Antimicrobial resistance (AMR) is a great concern in terms of global health for various reasons: it results in prolonged illness and greater risk of death, causes patients to be infected for a longer period of time leading to increased probability of spreading resistant microorganisms to others, and when infections stop responding to first-line drugs, more complex drugs are required and there is a possibility that all possibilities may be exhausted. Moreover, the longer duration of the infection and the treatment increases healthcare expenditure and the economic and social impact.
To give an example, each year 440,000 new cases of multiresistant tuberculosis are diagnosed, leading to at least 150,000 deaths around the world.
On 5, 6 and 7 November, national and international scientists and experts in this subject will meet at CosmoCaixa Barcelona called together by B·Debate and the Barcelona Institute for Global Health (ISGlobal) in collaboration with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Spanish Network for Research in Infectious Diseases (REIPI). The aim is to promote debate among public health authorities, regulatory bodies and pharmaceutical companies that participate in the prevention and treatment of infections caused by bacteria that are resistant to multiple drugs.
More information on the B·Debate website.
- Press release (31 October 2013)
- News on other B·Debate activities
| Organizers: |
  |
| Collaborators: |
   |